Lundin Law PC announces it is investigating claims against Osiris Therapeutics, Inc. ("Osiris" or the "Company") (NASDAQ: OSIR) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Osiris were false and misleading and/or failed to disclose material information regarding the Company's financial performance. To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at email@example.com. The investigation will focus on the Company's announcement that it has determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015, a decrease in product revenues of $1.0 million in the second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a decrease in product revenues of $1.1 million in 2014. When the truth was revealed, shares dropped causing investors harm. No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member. Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.